Lenalidomide-Associated ITP

Lenalidomide-Associated ITP

Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a ca...

Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP.

Chronic immune thrombocytopenic purpura (ITP) is due to platelet destruction by circulating antiplatelet antibody. Although autoantibodies against the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) complex and GPIb have been demonstrated using various methods, practical assays for detection of platelet-associated or plasma autoantibodies have not been available. We studied 59 patients with chronic...

ITP Platelet - associated and plasma anti - glycoprotein autoantibodies in chronic

Lenalidomide-associated hepatotoxicity--a case report and literature review.

BACKGROUND Lenalidomide is an immunomodulatory drug frequently used for treatment of patients with multiple myeloma and myelodysplastic syndromes. This report presents a rare case of lenalidomide-associated hepatotoxicity and reviews the available literature. CASE REPORT A 67-year-old male with multiple myeloma was hospitalized with nausea, vomiting and jaundice, while treated with a second t...

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

We conducted a literature review (1998 – July 2006) of venous thromboembolism (VTE) occurring among thalidomide or lenalidomide treated multiple myeloma patients. The overall VTE rate for thalidomide-treated multiple myeloma patients was 12% (585 reports among 4862 patients). The overall VTE rate among lenalidomide-treated multiple myeloma patients was 8% (110 reports among 1474 patients). VTE ...